Suven Pharmaceuticals share price

Balanced risk
  • 42%Low risk
  • 42%Moderate risk
  • 42%Balanced risk
  • 42%High risk
  • 42%Extreme risk
  • 1,006.35(-0.03%)
    June 19, 2025 11:17:50 AM IST
    • NSE
    • BSE
  • Vol : 50.76K (NSE + BSE)
    Last 20 day avg : 278.43 K

Suven Pharmaceuticals is trading -0.03% lower at Rs 1,006.35 as compared to its last closing price. Suven Pharmaceuticals has been trading in the price range of 1,018.00 & 1,002.45. Suven Pharmaceuticals has given -11.34% in this year & 0.73% in the last 5 days. Suven Pharmaceuticals has TTM P/E ratio 109.31 as compared to the sector P/E of 22.82.There are 6 analysts who have initiated coverage on Suven Pharmaceuticals. There are 3 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 38.73 Crores in its last quarter.Listed peers of Suven Pharmaceuticals include Glenmark Pharmaceuticals (-1.54%), Biocon (2.29%), Suven Pharmaceuticals (-0.03%).The Mutual Fund holding in Suven Pharmaceuticals was at 8.65% in 9 May 2025. The MF holding has increased from the last quarter. The FII holding in Suven Pharmaceuticals was at 7.38% in 9 May 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Jun 19, 2025, 05:54 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    15.15
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    96.89
    Higher than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.97
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.16
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
1,002.45
Highest
1,018.00
52 week range
Lowest
696.55
Highest
1,359.00
Suven Pharmaceuticals Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in March quarter by 58.94% from Rs 402.02 crore to Rs 252.93 crore, year-on-year
    • financial-insightsThe company's profit declined by 27.44% year-on-year during the March quarter, dropping from Rs 53.37 crore to Rs 38.73 crore
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Suven Pharmaceuticals Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 1,104.15
  • R2
  • 1,163.55
  • R3
  • 1,227.30
Pivot1,040.40
  • S1
  • 981.00
  • S2
  • 917.25
  • S3
  • 857.85
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Suven Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Glenmark Pharmaceuticals
Bullish
1,634.55-1.5446,127.1335.185.270.157.90
Biocon
Bullish
350.002.2942,021.0044.931.960.1459.81
Suven Pharmaceuticals
Bearish
1,006.35-0.0338,289.4095.2214.93-10.36
Laurus Labs
Bullish
658.80-0.6935,720.62112.597.960.1815.82
Ipca Laboratories
Bearish
1,348.15-1.0534,198.0639.164.960.298.55
Suven Pharmaceuticals Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Suven Pharmaceuticals is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holds a high stake in the company at 66.41%
    • InsightsPromoter(s) have increased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 3.67 percentage points from previous quarter
    • InsightsMutual Funds holding has decreased by 4.39 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    DSP Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 260.83
    • % of AUM 8.81
    ITI Pharma and Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 10.70
    • % of AUM 4.84
    Mirae Asset Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 104.34
    • % of AUM 3.88
    Invesco India Focused Fund Regular Growth
    5/5
    • Amount Invested (Cr.) 107.43
    • % of AUM 2.70
    UTI Healthcare Fund Regular Plan Growth
    NA
    • Amount Invested (Cr.) 28.14
    • % of AUM 2.65
    Suven Pharmaceuticals Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-28Audited Results
    2025-02-12Quarterly Results
    2024-11-12Quarterly Results
    2024-08-09Quarterly Results
    2024-05-30Audited Results
    About the company Suven Pharmaceuticals
    • IndustryBiotechnology & Drugs
    • ISININE03QK01018
    • BSE Code543064
    • NSE CodeCOHANCE
    Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
    • Management Info
    • Vivek SharmaAdditional Executive Chairman of the Board
    • Sudhir SinghChief Executive Officer
    • Himanshu AgarwalChief Financial Officer
    • Gaurav BahadurChief Human Resources Officer
    • Kundan JhaCompliance Officer and Company Secretary
    • Vetukuri Venkata Prasada RajuManaging Director, Executive Director
    Suven Pharmaceuticals Share Price FAQs

    Suven Pharmaceuticals is trading at 1006.35 as on Thu Jun 19 2025 05:47:50. This is -0.03% lower as compared to its previous closing price of 1006.70.

    The market capitalization of Suven Pharmaceuticals is 38289.40 Cr as on Thu Jun 19 2025 05:47:50.

    The average broker rating on Suven Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -

    • 3 analysts have given a strong buy rating
    • 3 analysts have given a buy rating
    • 0.00 analysts have given a hold rating
    • 0.00 analysts have given a sell rating
    • 0.00 analysts have given a strong sell rating

    The 52 wk high for Suven Pharmaceuticals is 1359.00 whereas the 52 wk low is 696.55

    Suven Pharmaceuticals can be analyzed on the following key metrics -

    • TTM P/E: 109.31
    • Sector P/E: 22.82
    • Dividend Yield: 0.00%
    • D/E ratio: 0.16

    Suven Pharmaceuticals reported a net profit of 264.77 Cr in 2025.

    The Mutual Fund Shareholding was 8.65% at the end of 9 May 2025.